Loading...
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer
Pancreatic cancer (PDAC) is still lacking of reliable markers to monitor tumor response. CA 19-9 is the only biomarker approved, despite it has several limitations in sensitivity and specificity. Since mutations of KRAS occur in more than 90% of tumors, its detection in circulating free tumor DNA (c...
Na minha lista:
| Udgivet i: | Sci Rep |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Publishing Group UK
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5554237/ https://ncbi.nlm.nih.gov/pubmed/28801547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-08297-z |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|